AngioDynamics (ANGO) Downgraded: Growth Priced In, Analyst Says

A Seeking Alpha analyst downgraded AngioDynamics (ANGO) on Monday, arguing the stock's recent rally has already priced in the company's operational improvements. The analyst, who has covered the stock twice before, said growth is working but the price knows it.

AngioDynamics makes devices used by physicians in minimally invasive procedures. The company focuses on three major sectors, including blood flow management. The analyst did not specify the other two sectors in the excerpt.

The downgrade reflects a view that the stock's appreciation has caught up with the underlying business momentum. The analyst sees limited upside from current levels, with the primary risk being that future catalysts are already discounted.

The analyst disclosed a beneficial long position in ANGO through stock ownership and wrote the article without compensation from the company, other than from Seeking Alpha.